Elevatebio LLC and Affini-T Therapeutics Inc. have entered into a partnership to advance Affini-T's engineered T-cell therapies focused on KRAS, an oncogenic driver mutation in solid tumor cancers.
Collplant Biotechnologies Ltd. and Ramot at Tel Aviv University Ltd., the technology transfer company of Tel Aviv University and Sheba Medical Center, have entered into a license and research agreement to codevelop a gut-on-a-chip tissue model for drug discovery and high-throughput screening of drugs.
Fresh off announcing a new $1.2 billion joint drug discovery and development project with Sanofi SA, Insilico Medicine Inc. founder and CEO Alex Zhavoronkov joined a chorus of executives at the Asia Summit on Global Health in proclaiming the critical importance of partnership between biopharma, tech companies, and regulators, even amid rising tensions between China and the West.
Biotheus Inc. has entered into a license and collaboration agreement with Hansoh Pharmaceuticals (Hansoh Pharmaceutical Group Co. Ltd.) for Biotheus' EGFR/MET bispecific antibody PM-1080 in Greater China, including mainland China, Hong Kong, Macao and Taiwan.
Ono Pharmaceutical Co. Ltd. has entered a worldwide drug discovery collaboration agreement with Captor Therapeutics SA to develop novel small-molecule degrader drugs against a currently undrugged target of interest in neurodegenerative diseases.
Fresh off announcing a new $1.2 billion joint drug discovery and development project with Sanofi SA, Insilico Medicine Inc. founder and CEO Alex Zhavoronkov joined a chorus of executives at the Asia Summit on Global Health in proclaiming the critical importance of partnership between biopharma, tech companies, and regulators, even amid rising tensions between China and the West.
The Alborada Drug Discovery Institute (ADDI) will collaborate with YD Global Life Science Co. Ltd. (YDGLS) to develop inhibitors of the unfolded protein response for the treatment of diseases that cause dementia.
Cyagen Biomodels LLC has established a strategic collaboration with Neurophth Therapeutics Inc. to codevelop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders.
Navrogen Inc. has entered into a cooperative research and development agreement (CRADA) with researchers at the U.S. National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Under this CRADA, Navrogen will sponsor the clinical investigation of the experimental antibody-drug conjugate (ADC) NAV-001, under supervision of the NCI.
RSS
